Navigation Links
Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
Date:10/31/2007

lecular microbiology and immunology at the MU School of Medicine. More importantly, it acts like a normal heart. This is the first time that we have concrete evidence that partial gene or cell therapies will be effective for preventing heart disease in a mouse model of muscular dystrophy.

Its important to note that this could improve the quality of life for individuals who have this heart condition, said Brian Bostick, a doctoral student in molecular microbiology and immunology and the first author of the study. Were also looking at this as a possible way to prevent heart disease. If we can treat it early through gene therapy or cell therapy, we know now that it can be very beneficial for patients.

The MU researchers said that this finding would have a positive impact on the ongoing gene and cell therapy studies in animal models of muscular dystrophy as well as in human patients. It also raises the hope of developing effective gene and cell therapies for patients suffering from other heart diseases.


'/>"/>

Contact: Christian Basi
BasiC@missouri.edu
573-882-4430
University of Missouri-Columbia
Source:Eurekalert

Page: 1 2

Related biology news :

1. Silence the gene, save the cell: RNA interference as promising therapy for ALS
2. Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers
3. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
4. Columbia research lifts major hurdle to gene therapy for cancer
5. Combination therapy boosts effectiveness of telomere-directed cancer cell death
6. Gene therapy converts dead bone graft to new, living tissue
7. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
8. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
9. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. Gene Therapy For Parkinsons Disease Moves Forward In Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... amyloids the fibrous protein deposits associated with diseases such ... potential new area for therapeutics. , It was believed that ... known as fibres - are inert, but that there may ... and cause disease. , But in a paper published ...
(Date:12/3/2009)... co-workers discovered that specific types of human papillomavirus (HPV) ... pathogens cause cells to degenerate. It is known today ... E7. Both proteins switch off different cellular control functions, ... Rsl and his co-workers at DKFZ have now discovered ...
(Date:12/3/2009)... likened to emptying a museum of its collection, or dumping ... replacing every local cuisine with McDonald,s burgers. , But the ... the world boring. New research now suggests it may also ... , "Habitat destruction and biodiversity loss,"driven by the replacement of ...
Breaking Biology News(10 mins):New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2Species down, disease up 2Species down, disease up 3Species down, disease up 4Lives Compromised and Patient Access Limited with New Cuts to Medicare 62021 1Lives Compromised and Patient Access Limited with New Cuts to Medicare 62021 2Statement of Support 3A Strengthening Oral Health Care is Key Part of Health Reform 62018 1Statement of Support 3A Strengthening Oral Health Care is Key Part of Health Reform 62018 2Shire Submits European Marketing Authorization Application 28MAA 29 for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 14957 1Shire Submits European Marketing Authorization Application 28MAA 29 for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 14957 2Shire Submits European Marketing Authorization Application 28MAA 29 for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 14957 3
... WASHINGTON Members of the public can send their ... mission dedicated to understanding the effects of particles in ... , The "Send Your Name Around the Earth" Web ... mission and place their names in orbit for years ...
... Enhanced Applicant,Verification and New Security Features that Combat ... 25 L-1 Identity,Solutions, Inc. (NYSE: ID ... today announced that the Massachusetts Registry of Motor ... a new six-year,contract to upgrade and further enhance ...
... surrounded by the San Bernardino National Forest have taken ... to a U.S. Forest Service study completed this summer., ... A Case Study on the San Bernardino National Forest," ... surveys and focus group discussions in 2007 had taken ...
Other Biology News:Send your name around the Earth on NASA'S Glory mission 2L-1 Identity Solutions Awarded New Massachusetts RMV Driver's License Contract Valued at an Estimated $32 Million 2L-1 Identity Solutions Awarded New Massachusetts RMV Driver's License Contract Valued at an Estimated $32 Million 3Study reveals homeowner perceptions in fire-prone areas 2
(Date:12/2/2009)... Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ... dose confirmation and dosimetry trial of Cotara® in patients ... brain cancer. Cotara is a targeted monoclonal antibody ... new treatment for GBM. Cotara specifically targets cells ...
(Date:12/2/2009)... - "Bolstering Biodiversity in Africa: ... Coinciding with the International Year of Biodiversity, ... international conference in Libreville,(Gabon) on the issue of ... attended by government and state leaders, ministers,scientific experts, ...
(Date:12/2/2009)... TechConnect World, an event bringing together the ... cleantech, nanotech, biotech and MEMS, announced the December ... ,, Now in its 14th year, TechConnect World, ... Institute (NSTI), and the Clean Technology and Sustainable ...
(Date:12/2/2009)... Ltd today announced data presentations on its novel oral ... 51st Annual Meeting and Exposition in New Orleans. ,, ... the Phase 1 dose-escalation trial of SB1518 detailing its ... ranging from 100 to 600 mg. These doses were ...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
... clinical-stage biopharmaceutical company focused on diseases of epidemic potential, ... for SQ109 with the dosing of the first cohort ... replace one or more of the current first-line antitubercular ... Fast Track designation and FDA/EMEA Orphan Drug Designation in ...
... Syrinx Consulting Corporation , an IT consulting ... SharePoint applications , announced today that ... a leading biopharmaceutical company in the Boston area. ... gigabytes of data from a SharePoint 2003 environment to ...
... biotechnology research is providing new applications for nutraceutical ... two leading health concerns among consumers. Leading ... www.advanascience.com , will present future ... consumer healthy category at VitaFoods International on Wednesday, ...
Other Biology Technology:Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109 2Syrinx Wins Contract with Leading Pharmaceutical Company for SharePoint 2007 Services 2Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications 2
...
... Cell Lines stably express the regulatory ... line is functionally tested for induction ... expression control vector pGene/V5-His/lacZ and by ... with mifepristone (Figure 1). These cell ...
... Kit Includes: Sufficient library for ... x 10^9 independent sequences, -28 gIII ... DNA sequencing, -96 gIII Sequencing Primer ... Host E. coli strain ER2738, Control ...
... Materials for 15-20 enhancements when ... Western Blot Signal Enhancement System is designed to ... is an excellent tool for evaluating proteins with low ... to pre-treat membrane prior to blocking the membrane; 1x ...
Biology Products: